Lineage Cell Therapeutics, Inc. Files Form 8-K with SEC

Lineage Cell Therapeutics, Inc., a biotechnology company, has filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC) on November 9, 2023. According to the filing, the company submitted 14 documents, including reports of material events and corporate changes. This filing is a mandatory disclosure requirement for publicly-traded companies, providing more current information on certain events than Forms 10-Q or 10-K.

Key Takeaways:

• Lineage Cell Therapeutics, Inc. submitted a Form 8-K with the SEC on November 9, 2023, containing 14 documents related to material events and corporate changes.
• The SIC code for Lineage Cell Therapeutics, Inc. is 2836, indicating its primary business activity is the development of biological products.
• The SEC filing includes reports of material events and corporate changes, which are of importance to investors and security holders.
• The Form 8-K filing provides more current information on certain events than Forms 10-Q or 10-K.
• The company's contact information listed in the filing is 2173 SALK AVENUE, SUITE 200, CARLSBAD, CA 92008, with a phone number of 510-521-3390.

Statistics:

• 14 documents were submitted with the Form 8-K filing.
• The SEC filing number is 0001493152-23-040057.
• The SIC code for Lineage Cell Therapeutics, Inc. is 2836.
• The company's filing with the SEC is for the "current report" of material events and corporate changes.

Sources:

• NewsRx LLC, "Lineage Cell Therapeutics, Inc. Files Form 8-K with SEC" (November 9, 2023)

Note: The exact format from the original source material for the date and first mention of the news article title is used without adding details.